Journal: Nature genetics
This publication is a review of current and emerging strategies for early cancer detection, with a focus on how cancer genomics is reshaping this field.
Key points:
- Early-stage detection remains the strongest predictor of good outcomes across many cancer types, despite therapeutic advances.
- Large-scale genomic studies have mapped somatic mutation and methylation patterns that are characteristic of specific cancers. These signatures now support assays that detect tumor-derived DNA from:
- Tissue biopsies
- Blood (liquid biopsies)
- Other body fluids
even at very early disease stages.
- Small clones with cancer-associated mutations are common in histologically normal tissues, especially with aging. These mutant clones:
- Are nearly universal in proliferative tissues in older individuals
- Progress to overt cancer in only a small fraction of people
- The review discusses how this background of “benign” or indolent mutant clones complicates early detection—because the mere presence of cancer-associated mutations does not necessarily mean clinically significant cancer.
- It synthesizes emerging data on the genetics and behavior of precancerous mutant clones and explains how these insights are being used to build prognostic frameworks. These frameworks aim to:
- Distinguish high-risk from low-risk individuals
- Identify which mutant clones are likely to progress
- Enable clinical “interception” of cancer at premalignant or very early malignant stages, when interventions are most effective.
Overall, the article integrates advances in mutation- and methylation-based detection technologies with evolving knowledge of clonal evolution in normal tissues, framing a path toward more precise, risk-adapted early detection and prevention strategies.